BioSpace News Archive

Amazentis, an innovative Swiss life sciences company pioneering scientific breakthroughs in nutrition, announced today the initiation of a randomized, double-blinded, placebo-controlled clinical trial in top athletes

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced its participation at the 64th Annual Meeting of the Japan Diabetes Society (May 20-22, 2021).

UTILITY therapeutics Ltd. announced that it has established a Scientific Advisory Board that will be chaired by Keith A. Rodvold, PharmD and Distinguished Professor of Pharmacy at the College of Medicine at the University of Illinois in Chicago.

Civis Analytics, a data science firm innovating at the intersection of public good and scientific best practices, today announced findings of an experiment to scientifically determine the most persuasive messaging for Americans most likely to be uncertain about COVID-19 vaccination.

IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that a significant majority of its shareholders have approved the resolution approving the previously announced investment in IntelGenx by ATAI Life Sciences AG, pursuant to which atai will initially acquire an approximate 25% interest in IntelGenx.

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a virtual fireside chat on Thursday, May 13, 2021, at the BofA Securities 2021 Healthcare Conference.

Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform

Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million provides funding to advance the R&D pipeline

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced it has entered into a definitive agreement to sell its miraDry business to 1315 Capital, a healthcare growth equity firm investing in commercial stage companies across medical devices, healthcare services, and therapeutics.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101, a novel therapeutic product candidate for the acute treatment of migraine, today reported financial results for the first quarter of 2021 and summarized recent business highlights.